Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722343 · ClinicalTrials.gov registry record · Phase 1
Exploratory Pharmacodynamic Study of Tenofovir-Based Products
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02722343 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 25 participants.
The verdict
NCT02722343, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This single site study is designed to describe and measure the efficacy of oral versus vaginal dosing of TFV-based products, specifically emtricitabine/tenofovir disoproxil fumarate oral tablets (Truvada) vs tenofovir intravaginal rings (IVR).
Interventions
- DRUG Truvada
- DRUG Tenofovir intravaginal ring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722343
The ClinicalTrials.gov registry entry for NCT02722343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Truvada is the first listed.
NCT02722343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722343 about?
NCT02722343 is a clinical study titled "Exploratory Pharmacodynamic Study of Tenofovir-Based Products". This single site study is designed to describe and measure the efficacy of oral versus vaginal dosing of TFV-based products, specifically emtricitabine/tenofovir disoproxil fumarate oral tablets (Truvada) vs tenofovir intravaginal rings (IVR).
What is the current status of trial NCT02722343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02722343?
The interventions under investigation include: Truvada (DRUG), Tenofovir intravaginal ring (DRUG).
Who is sponsoring clinical trial NCT02722343?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.